Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBT Margin (2020 - 2025)

Historic EBT Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 14.86%.

  • Cytek Biosciences' EBT Margin fell 151600.0% to 14.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.87%, marking a year-over-year decrease of 19500.0%. This contributed to the annual value of 2.84% for FY2024, which is 53000.0% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' EBT Margin is 14.86%, which was down 151600.0% from 14.86% recorded in Q2 2025.
  • Cytek Biosciences' 5-year EBT Margin high stood at 17.96% for Q4 2024, and its period low was 27.18% during Q1 2025.
  • Over the past 5 years, Cytek Biosciences' median EBT Margin value was 3.49% (recorded in 2022), while the average stood at 4.98%.
  • Per our database at Business Quant, Cytek Biosciences' EBT Margin plummeted by -249900bps in 2021 and then surged by 109000bps in 2024.
  • Over the past 5 years, Cytek Biosciences' EBT Margin (Quarter) stood at 1.14% in 2021, then surged by 646bps to 8.51% in 2022, then decreased by -17bps to 7.06% in 2023, then surged by 154bps to 17.96% in 2024, then tumbled by -183bps to 14.86% in 2025.
  • Its EBT Margin was 14.86% in Q3 2025, compared to 14.86% in Q2 2025 and 27.18% in Q1 2025.